Clopidogrel as adjunctive antiplatelet therapy during coronary stenting

Related Experiment Video

Updated: Oct 18, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

G J Mishkel1, F V Aguirre, R W Ligon

  • 1Prairie Educational and Research Cooperative, Division of Cardiology, Southern Illinois University School of Medicine, Springfield, USA. pccl@fgi.net

Journal of the American College of Cardiology
|December 10, 1999
PubMed

Insights

Aspirin plus clopidogrel is an effective antiplatelet therapy for preventing thrombotic complications and cardiovascular events after coronary stenting, showing similar safety and efficacy to aspirin plus ticlopidine.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Aspirin and ticlopidine are standard antiplatelet therapies post-coronary stenting.
  • Clopidogrel, with a similar mechanism to ticlopidine, requires further evaluation for efficacy and safety in this context.

Purpose of the Study:

  • To compare procedural and 30-day clinical outcomes of aspirin plus clopidogrel versus aspirin plus ticlopidine in patients undergoing coronary stenting.

Main Methods:

  • A single-center, prospective study of 875 patients undergoing coronary stenting.
  • Patients received aspirin with either clopidogrel (58.7%) or ticlopidine (41.3%).
  • Outcomes assessed included procedural success, subacute stent thrombosis, and 30-day major adverse cardiovascular events.

Main Results:

  • Procedural success rates were comparable: 99.6% for clopidogrel and 99.4% for ticlopidine.
  • Subacute stent thrombosis rates were low and similar: 0.2% for clopidogrel and 0.3% for ticlopidine (p=0.99).
  • Thirty-day rates of death, myocardial infarction, or target vessel revascularization were similar: 2.1% for clopidogrel and 1.4% for ticlopidine (p=0.57).

Conclusions:

  • Aspirin-plus-clopidogrel is an effective antiplatelet regimen for preventing thrombotic complications and major adverse cardiovascular events in diverse patients undergoing coronary artery stenting.
  • The combination therapy demonstrated comparable safety and efficacy to aspirin-plus-ticlopidine.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...